Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET
Company Participants
John Jordan - VP, Investor Relations and Corporate Communications
Jonathan Violin - CEO, President & Director
Kristian Humer - CFO, Chief Business Officer, Principal Financial Officer & Principal Accounting Officer
Conference Call Participants
Christopher Howerton - Jefferies
Thomas Smith - SVB Leerink
Laura Chico - Wedbush Securities
Rami Katkhuda - LifeSci Capital
Jason Butler - JMP Securities
Operator
Welcome to the Viridian Therapeutics First Quarter 2022 Conference Call. [Operator Instructions].
It is now my pleasure to introduce your host, John Jordan, Vice President of Investor Relations and Corporate Communications at Viridian. Please go ahead, sir.
John Jordan
Thank you, Debbie. Good afternoon, everyone, and welcome to our first quarter 2022 conference call. Today, after the market closed, we issued a press release providing our first quarter 2022 financial results and business updates. A replay of today's call will be available on our Investor Relations section of our website approximately 1 hour after its completion. After our prepared remarks, we will open up the call for Q&A.
Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these statements reflect our opinions only as of today.
Except as required by law, we specifically disclaim any obligation to update or revise these statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and our other reports filed with the SEC.
I would now
- Read more current VRDN analysis and news
- View all earnings call transcripts